{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:23:58Z","timestamp":1790645038679,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG057708"],"award-info":[{"award-number":["R01 AG057708"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG041851"],"award-info":[{"award-number":["R01 AG041851"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG011378"],"award-info":[{"award-number":["R01 AG011378"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG041851"],"award-info":[{"award-number":["R01 AG041851"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["K01 AG028573"],"award-info":[{"award-number":["K01 AG028573"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["U01 AG006786"],"award-info":[{"award-number":["U01 AG006786"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["P50 AG016574"],"award-info":[{"award-number":["P50 AG016574"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["K01 MH068351"],"award-info":[{"award-number":["K01 MH068351"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000867","name":"Robert Wood Johnson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000867","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neuropsychiatric symptoms (NPS) are a risk factor for cognitive impairment and are associated with cortical \u03b2-amyloid (A\u03b2) deposition. We conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging to examine the frequency of NPS among cognitively unimpaired (CU) and mild cognitive impairment (MCI) participants who either have normal (A\u2212) or abnormal (A+) A\u03b2 deposition. We also investigated whether combined presence of MCI and amyloid positivity (MCI\/A+) is associated with greater odds of having NPS as compared to CU\/A\u2212 (defined as reference group). Participants were 1627 CU and MCI individuals aged \u2265\u200950 years (54% males; median age 73 years). All participants underwent NPS assessment (Neuropsychiatric Inventory Questionnaire (NPI-Q); Beck Depression Inventory II (BDI-II); Beck Anxiety Inventory (BAI)) and <jats:sup>11<\/jats:sup>C-PiB-PET. Participants with an SUVR\u2009&gt;\u20091.42 were classified as A+. We conducted multivariable logistic regression analyses adjusted for age, sex, education, and APOE \u03b54 genotype status. The sample included 997 CU\/A\u2212, 446 CU\/A+, 78 MCI\/A\u2212, and 106 MCI\/A+ persons. For most NPS, the highest frequency of NPS was found in MCI\/A+ and the lowest in CU\/A\u2212. The odds ratios of having NPS, depression (BDI\u2009\u2265\u200913), or anxiety (BAI\u2009\u2265\u20098, \u2265\u200910) were consistently highest for MCI\/A+ participants. In conclusion, MCI with A\u03b2 burden of the brain is associated with an increased risk of having NPS as compared to MCI without A\u03b2 burden. This implies that the underlying Alzheimer\u2019s disease biology (i.e., cerebral A\u03b2 amyloidosis) may drive both cognitive and psychiatric symptoms.<\/jats:p>","DOI":"10.1038\/s41398-019-0456-z","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T13:02:46Z","timestamp":1553778166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Cortical \u03b2-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging"],"prefix":"10.1038","volume":"9","author":[{"given":"Janina","family":"Krell-Roesch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vassilaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter K.","family":"Kremers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val J.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanthi","family":"Vemuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Machulda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa J.","family":"Christianson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A.","family":"Syrjanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorazd B.","family":"Stokin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley M.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Traber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Knopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosebud O.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonas E.","family":"Geda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"key":"456_CR1","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1176\/appi.ajp.2014.13060821","volume":"171","author":"YE Geda","year":"2014","unstructured":"Geda, Y. E. et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study. Am. J. Psychiatry 171, 572\u2013581 (2014).","journal-title":"Am. J. Psychiatry"},{"key":"456_CR2","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1212\/WNL.0000000000001307","volume":"84","author":"A Pink","year":"2015","unstructured":"Pink, A. et al. Neuropsychiatric symptoms, APOE epsilon4, and the risk of incident dementia: a population-based study. Neurology 84, 935\u2013943 (2015).","journal-title":"Neurology"},{"key":"456_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000107100","volume":"24","author":"E Teng","year":"2007","unstructured":"Teng, E., Lu, P. H. & Cummings, J. L. Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer\u2019s disease. Dement. Geriatr. Cogn. Disord. 24, 253\u2013259 (2007).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"456_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3233\/JAD-2012-120169","volume":"31","author":"H Brodaty","year":"2012","unstructured":"Brodaty, H. et al. Neuropsychiatric symptoms in older people with and without cognitive impairment. J. Alzheimers Dis. 31, 411\u2013420 (2012).","journal-title":"J. Alzheimers Dis."},{"key":"456_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jagp.2013.01.006","volume":"21","author":"PB Rosenberg","year":"2013","unstructured":"Rosenberg, P. B. et al. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am. J. Geriatr. Psychiatry 21, 685\u2013695 (2013).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"456_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1017\/S1041610217002368","volume":"30","author":"J Krell-Roesch","year":"2018","unstructured":"Krell-Roesch, J. et al. Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. Int. Psychogeriatr. 30, 245\u2013251 (2018).","journal-title":"Int. Psychogeriatr."},{"key":"456_CR7","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.jagp.2016.08.007","volume":"24","author":"SE Holmes","year":"2016","unstructured":"Holmes, S. E. et al. beta-Amyloid, APOE and BDNF genotype, and depressive and anxiety symptoms in cognitively normal older women and men. Am. J. Geriatr. Psychiatry 24, 1191\u20131195 (2016).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"456_CR8","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/gps.4409","volume":"31","author":"F Yasuno","year":"2016","unstructured":"Yasuno, F. et al. High amyloid-beta deposition related to depressive symptoms in older individuals with normal cognition: a pilot study. Int. J. Geriatr. Psychiatry 31, 920\u2013928 (2016).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"456_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/0891988715606230","volume":"29","author":"JK Chung","year":"2016","unstructured":"Chung, J. K. et al. Cortical amyloid beta deposition and current depressive symptoms in alzheimer disease and mild cognitive impairment. J. Geriatr. Psychiatry Neurol. 29, 149\u2013159 (2016).","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"456_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1136\/jnnp-2013-306110","volume":"85","author":"T Mori","year":"2014","unstructured":"Mori, T. et al. Apathy correlates with prefrontal amyloid beta deposition in Alzheimer\u2019s disease. J. Neurol. Neurosurg. Psychiatry 85, 449\u2013455 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"456_CR11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1176\/appi.neuropsych.12060156","volume":"25","author":"GA Marshall","year":"2013","unstructured":"Marshall, G. A. et al. Apathy is associated with increased amyloid burden in mild cognitive impairment. J. Neuropsychiatry Clin. Neurosci. 25, 302\u2013307 (2013).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"456_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3233\/JAD-150181","volume":"49","author":"D Bensamoun","year":"2016","unstructured":"Bensamoun, D. et al. Associations between neuropsychiatric symptoms and cerebral amyloid deposition in cognitively impaired elderly people. J. Alzheimers Dis. 49, 387\u2013398 (2016).","journal-title":"J. Alzheimers Dis."},{"key":"456_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/JGP.0b013e3181953b82","volume":"17","author":"H Lavretsky","year":"2009","unstructured":"Lavretsky, H. et al. Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. Am. J. Geriatr. Psychiatry 17, 493\u2013502 (2009).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"456_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/WAD.0b013e31816c92bf","volume":"22","author":"MA Butters","year":"2008","unstructured":"Butters, M. A. et al. Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis. Assoc. Disord. 22, 261\u2013268 (2008).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"issue":"2Dementia","key":"456_CR15","first-page":"404","volume":"22","author":"RC Petersen","year":"2016","unstructured":"Petersen, R. C. Mild cognitive impairment. Contin. (Minneap. Minn.) 22(2Dementia), 404\u2013418 (2016).","journal-title":"Contin. (Minneap. Minn.)"},{"key":"456_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000115751","volume":"30","author":"RO Roberts","year":"2008","unstructured":"Roberts, R. O. et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 30, 58\u201369 (2008).","journal-title":"Neuroepidemiology"},{"key":"456_CR17","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1001\/archneur.1991.00530190071018","volume":"48","author":"E Kokmen","year":"1991","unstructured":"Kokmen, E., Smith, G. E., Petersen, R. C., Tangalos, E. & Ivnik, R. C. The short test of mental status: correlations with standardized psychometric testing. Arch. Neurol. 48, 725\u2013728 (1991).","journal-title":"Arch. Neurol."},{"key":"456_CR18","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412\u20132414 (1993).","journal-title":"Neurology"},{"key":"456_CR19","volume-title":"L\u2019examen Clinique en Psychologie","author":"A Rey","year":"1964","unstructured":"Rey, A. L\u2019examen Clinique en Psychologie (Presses Universitaires de France, Paris, 1964)."},{"key":"456_CR20","volume-title":"Wechsler Memory Scale-Revised","author":"D Wechsler","year":"1987","unstructured":"Wechsler, D. Wechsler Memory Scale-Revised (The Psychological Corporation, New York, 1987)."},{"key":"456_CR21","volume-title":"Boston Naming Test","author":"E Kaplan","year":"2001","unstructured":"Kaplan, E., Goodglass, H. & Weintraub, S. Boston Naming Test 2nd edn (Lippincott Williams & Wilkins, Philadelphia, 2001).","edition":"2nd edn"},{"key":"456_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1076\/jcen.20.2.194.1173","volume":"20","author":"JA Lucas","year":"1998","unstructured":"Lucas, J. A. et al. Mayo\u2019s Older Americans Normative Studies: category fluency norms. J. Clin. Exp. Neuropsychol. 20, 194\u2013200 (1998).","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"456_CR23","unstructured":"Wechsler, D. Wechsler Adult Intelligence Scale-Revised (Psychological Corporation, New York, 1981)."},{"key":"456_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","volume":"8","author":"RM Reitan","year":"1958","unstructured":"Reitan, R. M. Validity of the Trail Making Test as an indicator of organic brain damage. Percept. Mot. Skills 8, 271\u2013276 (1958).","journal-title":"Percept. Mot. Skills"},{"issue":"sup001","key":"456_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13854049208401877","volume":"6","author":"RJ Ivnik","year":"1992","unstructured":"Ivnik, R. J. et al. Mayo\u2019s Older Americans Normative Studies: WAIS-R norms for ages 56 to 97. Clin. Neuropsychol. 6(sup001), 1\u201330 (1992).","journal-title":"Clin. Neuropsychol."},{"issue":"sup001","key":"456_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/13854049208401879","volume":"6","author":"RJ Ivnik","year":"1992","unstructured":"Ivnik, R. J. et al. Mayo\u2019s Older Americans Normative Studies: WMS-R norms for ages 56 to 94. Clin. Neuropsychol. 6(sup001), 49\u201382 (1992).","journal-title":"Clin. Neuropsychol."},{"issue":"sup001","key":"456_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/13854049208401880","volume":"6","author":"RJ Ivnik","year":"1992","unstructured":"Ivnik, R. J. et al. Mayo\u2019s Older Americans Normative Studies: updated AVLT norms for ages 56 to 97. Clin. Neuropsychol. 6(sup001), 83\u2013104 (1992).","journal-title":"Clin. Neuropsychol."},{"issue":"sup001","key":"456_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/13854049208401878","volume":"6","author":"JF Malec","year":"1992","unstructured":"Malec, J. F. et al. Mayo\u2019s Older Americans Normative Studies: utility of corrections for age and education for the WAIS-R. Clin. Neuropsychol. 6(sup001), 31\u201347 (1992).","journal-title":"Clin. Neuropsychol."},{"key":"456_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183\u2013194 (2004).","journal-title":"J. Intern. Med."},{"key":"456_CR30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","volume":"256","author":"B Winblad","year":"2004","unstructured":"Winblad, B. et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med. 256, 240\u2013246 (2004).","journal-title":"J. Intern. Med."},{"key":"456_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1176\/jnp.12.2.233","volume":"12","author":"DI Kaufer","year":"2000","unstructured":"Kaufer, D. I. et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J. Neuropsychiatry Clin. Neurosci. 12, 233\u2013239 (2000).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"456_CR32","volume-title":"BDI-II, Beck Depression Inventory: Manual","author":"AT Beck","year":"1996","unstructured":"Beck, A. T., Steer, R. A. & Brown, G. K. BDI-II, Beck Depression Inventory: Manual 2nd edn (Psychological Corp.; Harcourt Brace, San Antonio, TX; Boston, MA, 1996).","edition":"2nd edn"},{"key":"456_CR33","volume-title":"BAI, Beck Anxiety Inventory: Manual","author":"AT Beck","year":"1990","unstructured":"Beck, A. T. & Steer, R. A. BAI, Beck Anxiety Inventory: Manual (Psychological Corp., Harcourt Brace Jovanovich, San Antonio, TX, 1990)."},{"key":"456_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack Jr.","year":"2017","unstructured":"Jack, C. R. Jr. et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 13, 205\u2013216 (2017).","journal-title":"Alzheimers Dement."},{"key":"456_CR35","doi-asserted-by":"publisher","first-page":"878","DOI":"10.2967\/jnumed.108.058529","volume":"50","author":"VJ Lowe","year":"2009","unstructured":"Lowe, V. J. et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J. Nucl. Med. 50, 878\u2013886 (2009).","journal-title":"J. Nucl. Med."},{"issue":"Pt 5","key":"456_CR36","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/brain\/awv050","volume":"138","author":"ME Murray","year":"2015","unstructured":"Murray, M. E. et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer\u2019s disease spectrum. Brain 138(Pt 5), 1370\u20131381 (2015).","journal-title":"Brain"},{"key":"456_CR37","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 270\u2013279 (2011).","journal-title":"Alzheimers Dement."},{"key":"456_CR38","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1176\/appi.ajp.2017.17040442","volume":"175","author":"NJ Donovan","year":"2018","unstructured":"Donovan, N. J. et al. Longitudinal association of amyloid beta and anxious-depressive symptoms in cognitively normal older adults. Am. J. Psychiatry 175, 530\u2013537 (2018).","journal-title":"Am. J. Psychiatry"},{"key":"456_CR39","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3233\/JAD-160979","volume":"56","author":"Z Ismail","year":"2017","unstructured":"Ismail, Z. et al. The Mild Behavioral Impairment Checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations. J. Alzheimers Dis. 56, 929\u2013938 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"456_CR40","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1001\/archpsyc.65.10.1193","volume":"65","author":"YE Geda","year":"2008","unstructured":"Geda, Y. E. et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch. Gen. Psychiatry 65, 1193\u20131198 (2008).","journal-title":"Arch. Gen. Psychiatry"},{"key":"456_CR41","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1001\/jama.288.12.1475","volume":"288","author":"CG Lyketsos","year":"2002","unstructured":"Lyketsos, C. G. et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA 288, 1475\u20131483 (2002).","journal-title":"JAMA"},{"key":"456_CR42","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jagp.2017.03.007","volume":"25","author":"YE Geda","year":"2017","unstructured":"Geda, Y. E., Krell-Roesch, J., Sambuchi, N. & Michel, B. F. Neuropsychiatric symptoms and neuroimaging biomarkers in alzheimer disease: \u201cwhich is the cart and which is the horse?\u201d. Am. J. Geriatr. Psychiatry 25, 694\u2013696 (2017).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"456_CR43","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jalz.2012.12.001","volume":"9","author":"YE Geda","year":"2013","unstructured":"Geda, Y. E. et al. Neuropsychiatric symptoms in Alzheimer\u2019s disease: past progress and anticipation of the future. Alzheimers Dement. 9, 602\u2013608 (2013).","journal-title":"Alzheimers Dement."}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0456-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0456-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0456-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T15:31:19Z","timestamp":1671204679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0456-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1038\/s41398-019-0456-z","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,28]]},"assertion":[{"value":"11 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.K.-R. receives funding from NIH and Roche. M.V. receives research funding from NIH, Roche, and Biogen. M.M.M. has consulted for Eli Lilly and Lysosomal Therapeutics, Inc. and receives unrestricted research grants from Biogen and Lundbeck, and research funding from the NIH\/NIA and Department of Defense. W.K.K. receives research funding from Department of Defense, NIH, Astra Zeneca, Biogen, and Roche. V.J.L. serves on scientific advisory boards for Bayer Schering Pharma, Piramal Life Sciences, and Merck Research and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH (NIA, NCI). P.V. receives NIH funding. M.M.M. receives funding from NIH. L.M.B. and M.T. are full-time employees of, and own shares at, F. Hoffmann-La Roche Ltd. C.R.J. serves on scientific advisory board for Eli Lilly and IDSMB for Roche. But he receives no compensation from any commercial entity. He receives research support from the NIH\/NIA and the Alexander Family Alzheimer\u2019s Disease Research Professorship of the Mayo Foundation. D.S.K. serves on a Data Safety Monitoring Board for the DIAN study. He is an investigator in clinical trials sponsored by Lilly Pharmaceuticals, Biogen, and the Alzheimer\u2019s Treatment and Research Institute at USC and receives research support from the NIH. R.O.R. receives research funding from the NIH\/NIA, Biogen, and Roche. R.C.P. is a consultant for Roche, Biogen, Merck, Eli Lilly, and Genentech. He receives publishing royalties from <i>Mild Cognitive Impairment<\/i> (Oxford University Press, 2003) and research support from the NIH. Y.E.G. receives funding from NIH and Roche and serves on Lundbeck Advisory Board. The other authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"123"}}